Delivery Order SPE2DB22D9367-SPE2DB25FSZ34
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $41,870.16 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of ICLUSIG 15 MG TABLET 30S, a pharmaceutical product, with a period of performance through April 10, 2024. This delivery order is issued under DMS Pharmaceutical Group's larger indefinite delivery vehicle (IDV) contract 4600082013 with DLA, valued at up to...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $41,870.16 contract is for the supply of the drug Iclusig 15 mg tablet in 30-count packages, with a completion date of November 19, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $171,788.80 on August 20, 2025, for the supply of Iclusig 30 mg tablets (30-count packages). The contract, with an ultimate completion date of September 11, 2025, is funded through the Defense Logistics Agency's Medical Supply Chain program and carries no set-aside designation. This delivery order is issued under DMS...
- The Department of Defense's Defense Logistics Agency awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $83,740.32, is for the supply of the prescription drug ICLUSIG 45 MG TABLET 30S. This delivery order is part of a larger indefinite delivery contract, valued at up to $4,999,999, that DMS Pharmaceutical Group holds with the Defense Logistics Agency to provide a broad range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $21,735.58 firm fixed-price delivery order is for the supply of ICLUSIG 30 MG TABLET 30S, a pharmaceutical product, with a period of performance through December 16, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
- This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $21,735.58 firm fixed-price delivery order is for the supply of ICLUSIG 30 MG TABLET 30S, a pharmaceutical product, with an ultimate completion date of October 1, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,471.16 fixed-price delivery order is for the supply of the drug Iclusig (ponatinib) 30 mg tablets. The contract is a part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm fixed-price...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $21,735.58 firm fixed-price delivery order is for the supply of ICLUSIG 30 MG TABLET 30S, a pharmaceutical product, with a performance period running through December 3, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract, SPE2DB25FYM54, valued at $41,870.16 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 4,566,357,367 units of the pharmaceutical product ICLUSIG 45 MG TABLET 30S. This delivery order is part of a larger Indefinite Delivery Contract (IDC), SPE2DB, valued at $499,999,999, which enables the DLA to issue firm fixed-price delivery...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $42,592.16, is for the delivery of the prescription drug Iclusig 15 mg tablet over the period ending March 10, 2025. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB...
- SPE2DB22D9367Indefinite Delivery Contract
- SPE2DB22D9367-SPE2DB25FSZ34Delivery Order
The Defense Logistics Agency awarded a $42,592.16 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 30 tablets of Iclusig 15 mg. The contract, issued on August 22, 2025, with an ultimate completion date of September 15, 2025, carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at approximately $500 million through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products to support military healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a key supplier in the federal pharmaceutical supply chain, consistently delivering specialized medications including oncology treatments, vaccines, biologics, and other prescription and over-the-counter drugs to Department of Defense healthcare sites. Iclusig (ponatinib), a tyrosine kinase inhibitor used in cancer treatment, represents the type of specialized pharmaceutical product the company regularly supplies to military medical facilities. The firm's contract performance demonstrates effective competition in federal procurement markets while leveraging its small business status to support DLA's mission of ensuring pharmaceutical availability across the military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $42.6k | 8/22/25 |